These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37790572)

  • 1. Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia.
    Sosero YL; Bandres-Ciga S; Ferwerda B; Tocino MTP; Belloso DR; Gómez-Garre P; Faouzi J; Taba P; Pavelka L; Marques TM; Gomes CPC; Kolodkin A; May P; Milanowski LM; Wszolek ZK; Uitti RJ; Heutink P; van Hilten JJ; Simon DK; Eberly S; Alvarez I; Krohn L; Yu E; Freeman K; Rudakou U; Ruskey JA; Asayesh F; Menéndez-Gonzàlez M; Pastor P; Ross OA; Krüger R; Corvol JC; Koks S; Mir P; De Bie RMA; Iwaki H; Gan-Or Z
    medRxiv; 2023 Sep; ():. PubMed ID: 37790572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Sosero YL; Bandres-Ciga S; Ferwerda B; Tocino MTP; Belloso DR; Gómez-Garre P; Faouzi J; Taba P; Pavelka L; Marques TM; Gomes CPC; Kolodkin A; May P; Milanowski LM; Wszolek ZK; Uitti RJ; Heutink P; van Hilten JJ; Simon DK; Eberly S; Alvarez I; Krohn L; Yu E; Freeman K; Rudakou U; Ruskey JA; Asayesh F; Menéndez-Gonzàlez M; Pastor P; Ross OA; Krüger R; ; Corvol JC; Koks S; Mir P; De Bie RMA; Iwaki H; Gan-Or Z;
    Mov Disord; 2024 Aug; ():. PubMed ID: 39132902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
    Martinez-Carrasco A; Real R; Lawton M; Iwaki H; Tan MMX; Wu L; Williams NM; Carroll C; Hu MTM; Grosset DG; Hardy J; Ryten M; Foltynie T; Ben-Shlomo Y; Shoai M; Morris HR
    medRxiv; 2023 May; ():. PubMed ID: 37425912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
    Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
    Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
    Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
    Kwon DK; Kwatra M; Wang J; Ko HS
    Cells; 2022 Nov; 11(23):. PubMed ID: 36496996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
    Dias CMV; Leal DAB; Brys I
    Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
    [No Abstract]   [Full Text] [Related]  

  • 9. High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.
    Shiraishi T; Nishikawa N; Mukai Y; Takahashi Y
    Parkinsonism Relat Disord; 2020 Jun; 75():80-84. PubMed ID: 32497995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.
    Santos-Lobato BL; Schumacher-Schuh AF; Rieder CRM; Hutz MH; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
    Arq Neuropsiquiatr; 2020 Apr; 78(4):206-216. PubMed ID: 32294749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia.
    Jeong EH; Sunwoo MK; Song YS
    Front Neurol; 2018; 9():1133. PubMed ID: 30619078
    [No Abstract]   [Full Text] [Related]  

  • 12. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
    Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
    J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
    Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
    Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
    Yan JH; Ge YL; Wang PZ; Li W; Jin H; Zhang JR; Chen J; Wang F; Li D; Mao CJ; Li K; Liu CF
    Neurosci Lett; 2023 Mar; 801():137140. PubMed ID: 36813078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are LRRK2 p.G2019S or GBA1 variants associated with long-term outcomes of deep brain stimulation for Parkinson's disease?
    Anis S; Goldberg T; Shvueli E; Kozlov Y; Redlich Y; Lavi N; Lavie I; Sosero YL; Gan-Or Z; Ungar L; Zibly Z; Greenbaum L; Fay-Karmon T; Hassin-Baer S
    Parkinsonism Relat Disord; 2024 Jul; 124():106008. PubMed ID: 38242744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort.
    Eusebi P; Romoli M; Paoletti FP; Tambasco N; Calabresi P; Parnetti L
    NPJ Parkinsons Dis; 2018; 4():33. PubMed ID: 30480086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Analysis Identifies New Loci Associated With Motor Complications in Parkinson's Disease.
    Ryu HS; Park KW; Choi N; Kim J; Park YM; Jo S; Kim MJ; Kim YJ; Kim J; Kim K; Koh SB; Chung SJ
    Front Neurol; 2020; 11():570. PubMed ID: 32733355
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
    Kaplan N; Vituri A; Korczyn AD; Cohen OS; Inzelberg R; Yahalom G; Kozlova E; Milgrom R; Laitman Y; Friedman E; Rosset S; Hassin-Baer S
    J Mol Neurosci; 2014 Jun; 53(2):183-8. PubMed ID: 24633632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease.
    Athulya RT; Jayakrishnan S; Iype T; Rajan R; Alapatt PJ
    Ann Indian Acad Neurol; 2020; 23(1):44-47. PubMed ID: 32055121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
    Wang CC; Wu TL; Lin FJ; Tai CH; Lin CH; Wu RM
    Eur J Neurol; 2022 Apr; 29(4):1044-1055. PubMed ID: 34962701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.